uniQure Raises $345M in Public Offering
uniQure has successfully raised $345M in a Public Offering led by Public Markets.
Company Overview
uniQure is a HealthTech company headquartered in Amsterdam, Netherlands, founded in 1998 with 600+ employees.
Gene therapy company developing AMT-130 for Huntington's disease treatment
Fundraising Details
- Amount Raised: $345M
- Round Type: Public Offering
- Date: 2025-09-08
- Investors: Public Markets
About uniQure
Gene therapy company developing AMT-130 for Huntington's disease treatment The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Amsterdam, Netherlands
- Founded: 1998
- Team Size: 600+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in uniQure's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. uniQure's successful fundraising reflects the strong fundamentals and growth potential in this space.
Looking Ahead
With this new capital, uniQure is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-09-08. For more information about uniQure, visit their headquarters at Amsterdam, Netherlands.
